Effects of L-Carnitine in Amyotrophic Lateral Sclerosis Patients With CHCHD10 Mutations
The trial investigates the safety and efficacy of L-carnitine in ALS patients with specific CHCHD10 mutations. Given the limited treatment options for ALS, a successful outcome could position L-carnitine as a novel therapeutic approach, potentially expanding its market presence in neuromuscular disorders. The competitive landscape includes existing ALS therapies, but the specificity to CHCHD10 mutations may provide a unique market niche. Diligence should focus on the trial's safety profile and efficacy data, as well as potential regulatory pathways for approval in this specific patient population.
Indication: Amyotrophic Lateral Sclerosis (ALS)
Modality: small molecule
Target: CHCHD10 mutations in Amyotrophic Lateral Sclerosis (ALS) patients.
Sponsor: ChaodongWang
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 07, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CHCHD10 mutations in Amyotrophic Lateral Sclerosis (ALS) patients.
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis (ALS)
Condition normalized: Amyotrophic Lateral Sclerosis (ALS)
Modality raw: small molecule
Modality normalized: small molecule
Target raw: CHCHD10 mutations in Amyotrophic Lateral Sclerosis (ALS) patients.
Target normalized: CHCHD10 mutations in Amyotrophic Lateral Sclerosis (ALS) patients.